In cisplatin-induced AKI mouse models, neutralizing IL-33 therapy can reduce CD4+ T cell infiltration in the kidneys, lowered serum creatinine levels, and alleviate acute tubular necrosis (ATN) and cellular apoptosis. Here, IL33 is linked to acute kidney injury.